The European Medicines Agency (EMA) has recommended the conditional approval of Zemcelpro®, a promising new stem cell-based Advanced Therapy Medicinal Product (ATMP) designed to treat adults with haematological malignancies, including leukaemia, lymphoma, myeloma, and myelodysplastic syndrome, who lack a suitable stem cell donor for transplantation.
Traditionally, stem cells for transplant are taken from a matched sibling or unrelated donor. When these are unavailable, umbilical cord blood can be used. But these units often contain too few stem cells, leading to delayed engraftment – the crucial process by which transplanted cells establish themselves in the patient’s bone marrow. Zemcelpro® overcomes this obstacle by including dorocubicel, a component made of stem cells that have been expanded or multiplied outside the body. This boosts the total number of viable cells available for transplantation, helping to speed up engraftment and recovery.
The EMA’s recommendation is based on results from two preliminary clinical studies involving 25 patients, which showed promising results though the patient group was small, representing a significant step forward for patients with limited treatment options.
Like many advanced therapies, Zemcelpro® is not without risks. In a broader group of 116 patients, some side effects were observed. To address these concerns, the EMA has outlined a risk management plan, including careful patient monitoring and specific strategies to reduce the likelihood and severity of these effects. Consistently, Zemcelpro® has been granted a conditional marketing authorisation, meaning that the EMA acknowledges the necessity to allow early access to this treatment as it fills a critical unmet need, but the manufacturer must provide further data, including results from a randomised controlled trial and a patient registry.
The positive opinion now moves to the European Commission, which will make the final decision on EU-wide approval.
Zemcelpro® represents a new frontier in stem cell therapy, particularly for patients who previously had few or no options. By expanding the use of umbilical cord blood, Zemcelpro® offers a precious treatment option to those with life-threatening blood cancers who cannot find a suitable donor.
For more information on Zemcelpro® and upcoming regulatory decisions, visit the European Medicines Agency (EMA) website.